Skip to content

Effect of supplements containing fermented black garlic on hepatic function - a parallel randomized trial-.

Effect of supplements containing fermented black garlic on hepatic function - a parallel randomized trial-. - Effect of fermented black garlic on hepatic function.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000024771
Enrollment
40
Registered
2016-12-01
Start date
2016-03-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Capsule containing fermented black garlic 334 mg of the garlic/day Placebo capsule not containing fermented black garlic

Sponsors

Faculty of Agriculture, Kyushu University
Lead Sponsor
Faculty of Humanity-Oriented Science and Engineering, Kindai University
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) persons who is generally judged as healthy (2) persons who feel change in their body shapes and/or disturbance of the life

Exclusion criteria

Exclusion criteria: (1) persons who have any dietary supplements, quasi drugs or medicines which cause same or similar efficacy with the effect evaluated in this study (2) persons who have changed their habitats to take supplements within past 4 weeks. (3) Persons who work in night shift or in day and night shift (4) persons who have been treated their illness or prevention in a clinic at their informed consent (5) persons with their medical histories as follows: serious diseases of sugar metabolism,lipid metabolism, hepatic function, renal function, heart, circulatory, respiratory, endocrine system, immune system, or mental illness of the nervous system (6) persons with the medical histories of alcoholism or drug dependence (7) persons who might be developed allergic reaction to foods. (8) Persons who are pregnant, breast-feeding, or hope to be pregnant during the study period (9) persons who had always participated in or will participate in any other clinical trial (to use foods/medicine/quasi medicine/medical device) (10) persons who will not be judged suitable to the participants by the investigator.

Design outcomes

Primary

MeasureTime frame
Hepatic function (AST, ALT, LD, gamma-GTP, LAP)

Secondary

MeasureTime frame
Renal function (Urea nitrogen, Creatine, Uric acid) Sugar metabolism (glucose, HbA1c) Lipid metabolism (HDL-cholesterol, LDL-cholesterol, Triglycerides) Physical measurements (Body weight, Body fat percentage, waist circumference, systolic blood pressure, diastolic blood pressure, heart beat)

Countries

Japan

Contacts

Public ContactKuniyoshi Shimizu

Faculty of Agriculture, Kyushu University Laboratory of Systematic Forest and Forest Products Science

shimizu@agr.kyushu-u.ac.jp092-642-3002

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026